Skip to main content

Future biomedical leaders, innovators, or entrepreneurs looking to accelerate the translation of ideas into high-quality and differentiated biomedical products.​

Apply Now

Deadline November 15, 2022

Gain a real-world understanding of translational science applied to the discovery/design and development of biomedical products including drugs/biologics, cell & gene therapies, and medical technology.

This certificate is ideal for individuals with the motivation and potential to become leaders, innovators, or entrepreneurs:

  • Biomedical and healthcare professionals
  • Postdoctoral scholars in a scientific, engineering, or business field

About the Certificate

We offer maximal flexibility for the working professional:
  • Classes on weekday evenings 6 to 8 pm Pacific Time
  • Hands-on learning approach taught by a faculty of experienced biomedical industry leaders.
  • Once a week, one course per quarter
  • Four courses total, each offered once a year
  • Flexibility to complete the certificate within 1 to 5 years with commitment to only one course at time

Our multidisciplinary faculty team constantly co-develops and updates course content, providing expertise on emerging knowledge and practices in their respective fields, thus ensuring that the certificate program remains up to date in the rapidly evolving discipline that is translational science.

Multiple Areas of Interest

  • Biomarkers 
  • Omics 
  • Precision medicine 
  • Translational imaging 
  • Intellectual property 
  • Biotechnology 
  • Drugs/Biologics
  • Cell & gene therapy 
  • Diagnostics 
  • Medical devices 
  • Digital health

Roles obtained by our alumni and current students

  • Principal Scientist - Biotechnology company
  • Assistant Project Scientist - University
  • Scientist, In Vivo Pharmacology - Pharmaceutical company
  • Senior Business System Analyst - Biopharmaceutical company
  • Senior Veterinary Scientist, Study Director, & Medical Device Team Lead - Contract research organization
  • Director, Statistical Programming & Analytics - Biotechnology company
  • Research Scientist I, Discovery Pharmacology - Biopharmaceutical company
  • Scientist II - Biotechnology company
  • Senior Scientist I, Clinical Immunology - Biotechnology company

Apply Now

Deadline: November 15, 2022

Real-Time online weekly Zoom lessons

TSC-Program-Schedule-image.png

Translational Research Fundamentals (CLRE-236)

Learn and discuss the various topics that encompass translational science.

Learn about the application of translational science principles and tools to the discovery/design and development of biomedical products. Encompassing everything from drugs/biologics and cell & gene therapy to medical technology.

Topics are taught by a different expert faculty from the biomedical industry invited each week.

Lesson Topics:

  • Overview of Translational Medicine & Biomarkers 
  • Omics Tools
  • Functional Omics Analysis / Precision Medicine 
  • Translational Imaging
  • Diagnostics
  • Drug Discovery
  • Non-Clinical Development
  • Clinical Development
  • Cell & Gene Therapy
  • Medical Technology

Applied Translational Research (CLRE-238)

The complete arch from ideation of a new biomedical product to marketing authorization for the diagnosis or treatment of patients.
The course is taught using as an example a family of drugs used to treat one the most prevalent chronic diseases today. The course will illustrate the critical analysis of all the steps necessary to progress a new idea into clinical development and to the market. Through carefully designed home assignments the students will learn the fundamentals of how to analyze the relevant literature and publicly available data. The students will also have opportunities to discuss with the faculty their real-world experience in the pharmaceutical industry.

 Using drugs as the archetypal biomedical product you will learn how to perform critical analysis of the following tasks:

  • Evaluate the science behind the new concept and potential for translatability to humans
  • Determine which additional fundamental research may be needed
  • Assess whether real-world conditions are favorable for going into proof of concept in patients
  • Assess the regulatory environment
  • Identify the Investigational New Drug (IND)- enabling pre-clinical activities
  • Define clinical development activities needed to reach proof of concept in patients (the true translational step)
  • Determine clinical development activities needed to obtain drug approval for desired indication(s)
  • Assess market penetration and pricing
  • Assess post-marketing activities
  • Assess life cycle management and competition 

Applied Translational Research II (CLRE-239)

Now it's your turn to show what you have learned so far
This course applies the translational scientific knowledge acquired in previous courses to create a comprehensive plan to develop a new biomedical product.
Students are divided into cross-functional teams and assigned a drug class and indication to develop, focusing on a different translational science concept each week. Each team is guided/mentored by a pharmaceutical industry veteran.

Scenarios where this is fundamental:
  • New academic discovery – should it be carried into translational activities?
  • New mechanism of action, pathway, molecular target, cell type, drug, metabolite, protein, etc.
  • Perform a proof-of-concept trial in patients with a "prototype" biomedical product in an academic environment. Publish and let the biomedical industry discover/design a bona fide biomedical product.
  • Start up a pharmaceutical, biotechnology, or medical technology company based on a new academic discovery
  • Promote a new project at a pharmaceutical, biotechnology, or medical technology company
  • Perform a due diligence exercise at a pharmaceutical, biotechnology, or medical technology company for in-licensing a biomedical product
  • As background while involved in any role in biomedical product discovery/design & development in a pharmaceutical, biotechnology, or medical technology company
  • As background while involved in clinical development in academia/research institutions
  • As background for independent professional occupation
  • Intellectual property lawyer, venture capital evaluator, patent agent, physician, pharmacist, therapist, medical writer, etc.

Capstone Project: Certificate Project (CLRE-40004)

The Capstone project is the certificate program's culminating activity. Through this activity, students, working in teams or individually, apply their learnings gained from prior courses and their own experience as professionals. The project focuses on addressing the needs that actual life science companies or academic groups have in the translational science and/or business areas. Such efforts could include new asset due diligence assessment, positioning research, indication selection investigation, Investigational New Drug (IND) application development, Investigator’s Brochure (IB) creation, and clinical trial protocol writing. At the end of the project, the students present the final deliverable to course faculty and the client company management or academic group leadership for evaluation. This last stage successfully completes the certificate and, most importantly, aids the student's career development with valuable skills and experience.

Key Documents

For any Certificate questions, please contact us directly:

Dr. M. Paz Rodriguez, Communication Director
Email: mpr002@health.ucsd.edu


Leadership and Faculty

Apply Now

Leadership

  • Regent Laporte, DVM, MSc, PhD - Program Director
  • Claudio D. Schteingart, PhD
  • Maria Paz Rodriguez, DDS, MAS - TSC Communications

General Administration

  • Andrea P. Laserna, BS - Program Manager
  • Tiana Mack-Miller, BS - Communication Assistant

Faculty

CLRE-236 Translational Research Fundamentals

  • Regent Laporte, DVM, MSc, PhD - Course Director
  • Maria Paz Rodriguez, DDS, MAS - Course Co-Director
  • Roberta V. Alexander, PharmD, PhD
  • Andrew Baker, BEng (Hons)
  • Elizabeth Brunk, PhD
  • Timothy R. Geiger, PhD
  • Mark S. Hixon, PhD
  • Kanthi A. Kollengode, MD, MAS
  • Patrick McConville, PhD
  • Daniel Oliver, MBA
  • Pierre Riviere, PhD
  • Marina Seme Nelson, PhD

CLRE-238 Applied Translational Research

  • Regent Laporte, DVM, MSc, PhD - Course Director
  • Claudio D. Schteingart, PhD - Course Co-Director
  • Maria Paz Rodriguez, DDS, MAS – Course Manager
  • Stephen L. Bender, PhD
  • Thomas Bicsak, PhD
  • Michael K. Dunn, PhD, MBA
  • Mark Fineman, MAS, MS, PhD
  • Wolfgang Glaesner, PhD
  • David G. Parkes, PhD

CLRE-239 Applied Translational Research II

  • Regent Laporte, DVM, MSc, PhD - Course Director
  • Claudio D. Schteingart, PhD - Course Co-Director
  • Maria Paz Rodriguez, DDS, MAS – Course Manager
  • Steven L. Bender, PhD
  • Jury Panel for Final Presentations
    • Mark Fineman, MAS, MS, PhD
    • Mark S. Hixon, PhD
    • Kanthi A. Kollengode, MD, MAS

CLRE-40004 Capstone Project

  • John M. York, PharmD, MBA - Course Director
  • Maria Paz Rodriguez, DDS, MAS - Course Co-Director​

 

Apply Now

 

Roberta V. Alexander, PharmD, PhD

Dr. Roberta Alexander has over 20 years of pharmaceutical and diagnostics industry experience across multiple therapeutic areas including rheumatology, gastroenterology, pain, endocrinology, inflammation, and cardiovascular diseases. She has a unique background encompassing clinical and preclinical research. Currently, Dr. Alexander serves as Senior Director of Clinical Research & Medical Affairs at Exagen, a diagnostics company, where she oversees clinical research and business development.
Dr. Alexander obtained her PharmD degree and her PhD in Molecular Pharmacology from the Università degli Studi di Perugia, Italy. She then completed a Postdoctoral Fellowship in Molecular Pharmacology at the School of Medicine of the University of Pennsylvania.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Alexander teaches about diagnostics in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program. 

 

Andrew Baker, Beng (Hons)

Mr. Andrew Baker is a medical technology industry expert with over 30 years of experience. A graduate of the University of Portsmouth, he has managed industrial and medical solutions at Maxim Integrated (now part of Analog Devices) for over 11 years. Currently, as Managing Director of the Vital Signs Monitoring Solutions Business Unit, Mr. Baker is leading a team of engineers focused on developing solutions for Wearable Health, focusing on power management and sensing technologies. Mr. Baker received his BEng (Hons) in Electrical Engineering from the University of Portsmouth. At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Mr. Baker teaches about medical technology in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 

Steve L. Bender, PhD

Dr. Steve Bender has over 25 years of drug discovery experience primarily focused on Oncology and, more recently, in Immuno-Oncology, and spanning both small molecule and biotherapeutic approaches.  At the Genomics Institute of the Novartis Research Foundation (GNF), he led a group of approximately 60 cancer biologists and immunologists as the Executive Director of Cancer Therapeutics. During his tenure, the Cancer Therapeutics teams discovered six novel drug candidates that have progressed into clinical trials. He is now Entrepreneur in Residence at Boxer Capital, as well as Founder and Principal Consultant at NexTx Insights.
Dr. Bender received his BS in Chemistry from the University of Illinois Urbana-Champaign and his PhD in Organix Chemistry from Harvard University.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Bender teaches about small molecules as drug chemical modality and about Oncology Drug Discovery & Development in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program. He also mentors a student team in an Oncology drug case study in the Applied Translational Research II (CLRE-239) course.

 

Thomas Bicsack, PhD

Dr. Thomas Bicsak is a regulatory affairs professional with nearly 30 years of experience in all phases of drug development. He is currently Founder and Principal at RPQ Consulting, providing strategic regulatory consulting services to biotech and pharmaceutical companies developing products across a wide variety of therapeutic indications. Prior to this, Dr. Bicsak was Vice President of Regulatory Affairs and Quality at Biosplice Therapeutics (previously known as Samumed), overseeing regulatory strategy for all development programs. 
Dr. Bicsak received his BA (Hons) in Biochemistry from Rutgers University and his PhD in Chemistry from the University of California, San Diego, where he then completed a Postdoctoral Fellowship in Reproductive Endocrinology at the School of Medicine. 
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Bicsak teaches about regulatory affairs in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program.

 
Elizabeth C. Brunk, PhD

Dr. Elizabeth Brunk is an experienced academic computational scientist who is a consultant for the pharmaceutical industry. She is currently an Assistant Professor at the Department of Pharmacology and the Department of Chemistry of the University of North Carolina, where she is also a faculty of the Integrative Program for Biological & Genome Sciences, the Lineberger Cancer Center, and the Computational Medicine Program. Dr. Brunk’s research focuses on the identification of functionally relevant variants in cancer, the understanding of how molecular pathways and variants drive drug response, the development of methods to integrate cancer omics data across biological scales, and the development of tools for functional/precision medicine.
Dr, Brunk received her BS in Biochemistry from the University of Michigan, her MSc in Chemistry and Molecular Modeling of Biomolecular Systems jointly from the University of Amsterdam, The Netherlands, and the École normale supérieure de Lyon, France, and her PhD in Computational Chemistry from the École Polytechnique Fédérale de Lausanne, Switzerland. She then completed a Postdoctoral Research Fellowship offered jointly by the University of California, Berkeley, and the Joint BioEnergy Institute of the US Department of Energy. More recently, she completed a Postdoctoral Fellowship in the Cancer Therapeutics Training Program at the Moores Cancer Center of the University of California, San Diego.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Brunk teaches about functional/precision medicine in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 

Michael K. Dunn, PhD, MBA

Dr. Michael Dunn is an intellectual property and scientific intelligence professional with over 20 years of pharmaceutical industry experience. He is currently Senior Director of Scientific Information & Intelligence at the Ferring Research Institute and a member of Ferring Pharmaceuticals’ Global Patent Department.  His responsibilities include patent strategy and prosecution for drug discovery projects, scientific competitive intelligence, and research reporting. Dr. Dunn has notably published on the impact of patent timing on pharmaceutical product exclusivity, on peptide therapeutics, and on data integrity in research environments.
Dr. Dunn received his PhD in Biological Chemistry & Molecular Pharmacology from Harvard Medical School and his MBA from the Johnson Graduate School of Management of Cornell University. He is also a certified Patent Agent.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Dunn teaches about innovation and intellectual property in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program.

 

Mark Fineman, MAS, MS, PhD

Dr. Mark Fineman is a seasoned pharmaceutical executive with over 30 years of experience leading R&D for both public and private companies. In these roles, he has led the strategy and execution of multiple programs ranging from early discovery through global commercialization of several first-in-class products. He is currently Chief Development Officer at Glyscend, a biopharmaceutical company developing novel orally-delivered drug candidates that work on targets inside the gastrointestinal tract to treat a variety of metabolic disorders, including type 2 diabetes.
Dr. Fineman received his Master of Advanced Studies in Clinical Research and his MS in Molecular Pathology from the University of California, San Diego, and his PhD in Medicine from the Vrije Universiteit Amsterdam, The Netherlands.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Fineman teaches a drug case study in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program.
 

Timothy Geiger, PhD

Dr. Timothy Geiger has over 20 years of experience in the biotechnology and pharmaceutical industries. He is currently Senior Manager of Field Application Scientists for the Southwest Business Unit at ProteinSimple, a subsidiary of Bio-Techne Corp., a biotechnology and clinical diagnostic holding company. Before getting involved in the biotechnology industry, Dr. Geiger was a Scientist at Allergan, a pharmaceutical company, where he was overseeing a team of analysts developing molecular biology and immune-based analytical methods for drug development.
Dr. Geiger received his PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Geiger teaches about omics tools in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.


 Wolfgang Glaesner, PhD

Dr. Wolfgang Glaesner is a protein biochemist with over 20 years of experience in the discovery and development of peptide, protein, and antibody therapeutics. He is currently the Chief Scientific Officer of Biotechnology Research & Development at the Lilly Biotechnology Center in San Diego, a part of the pharmaceutical company Eli Lilly. In this role, Dr. Glaesner focuses on the discovery and engineering of peptides and antibodies across all therapeutic areas, as well as the development of novel molecular formats, such as bi-specific antibodies, fusion antibodies, and antibody-drug conjugates. Notably, he led the discovery team that designed dulaglutide (TRULICITY), a best-in-class drug in the type 2 diabetes space.
Dr. Glaesner received his PhD in Biochemistry from the University of Göttingen, Germany, and completed a Postdoctoral Fellowship in Protein Chemistry at the pharmaceutical company Novartis, Basel, Switzerland.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Glaesner teaches about biologics in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program. 

 

Mark S. Hixon, PhD 

Dr. Mark Hixon is an innovative and multidisciplinary pharmaceutical industry professional with a successful record in drug development and over 20 years of experience. He is currently Senior Director of Biosimulation at VeriSIM Life, a contract research organization, where he focuses on project strategic guidance and building translational bridges of clinical relevance. Earlier in his career, Dr. Hixon spent 14 years at Takeda Pharmaceuticals, where he notably led modeling and simulation efforts to make seminal contributions to multiple drug discovery and development project teams.
Dr. Hixon received his PhD in Medicinal Chemistry from the University of Kansas.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Hixon teaches about clinical development in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 
Kanthi A. Kollengode, MD, MAS 

Dr. Kanthi Kollengode is currently Senior Clinical Trial Physician for Clinical Research & Development at the pharmaceutical company Bristol-Myers Squibb, where she is also Lead Physician for the Phase 3 Trials for Crohn’s Disease, and Lead Physician for the Pediatric Inflammatory Bowel Disease Program. She received her MD degree from the Rajiv Gandhi University of Health Sciences in Bangalore, India, where she focused on health education and outreach while working in free clinics and organizing health education and prevention programs for schools. Dr. Kollengode then completed a Clinical Research Fellowship in Hematology/Oncology at the University of Southern California and obtained her Master of Advanced Studies in Clinical Research at the University of California, San Diego.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Kollengode teaches about biomarkers and diagnostics in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.
 
Regent Laporte, DVM, MSc, PhD

Dr. Regent Laporte is a scientific leader in Translational Pharmacology with over 20 years of experience in the biotechnology and pharmaceutical industry across multiple therapeutic areas, including Emergency and Critical Care Medicine, Hepatology, Gastroenterology, Urology, and Reproductive Health. He is Founder and Principal Consultant at Laporte & Associates, a biotechnology and pharmaceutical R&D consulting company, and Senior Director of Translational Pharmacology at Peptide Logic, a biopharmaceutical startup company combining the advantages of synthetic peptides and recombinant antibodies to create innovative semi-synthetic biologics for the treatment of pain and other pathological conditions in select therapeutic areas. Previously, he was Director of Exploratory Pharmacology at Ferring Pharmaceuticals. 
Dr. Laporte received his DVM and his MSc in Veterinary Anatomy and Physiology from the Université de Montréal, Canada. He received his PhD in Pharmacology from the University of Vermont College of Medicine and completed Postdoctoral Fellowships in Cardiology and in Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Laporte is Program Director of the Translational Science Certificate, Module Director of the Concentration in Translational Science of the Master of Advanced Studies in Clinical Research, and Course Director of Translational Research Fundamentals (CLRE-236), Applied Translational Research (CLRE-238), and Applied Translational Research II (CLRE-239).

Andrea P. Laserna, BS - Program Manager

Tiana Mack-Miller, BS - Communication Assistant
 
Patrick McConville, PhD

Dr. Patrick McConville has extensive knowledge in translational imaging, with over 20 years of industry experience in preclinical imaging for drug discovery and development applications, such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), bioluminescence, fluorescence, and 2-dimensional X-ray. He is currently Vice President of the contract research organization inviCRO, which launched the first multi-modality imaging center in San Diego. In addition, he also serves as Professor of Practice in Radiology at the School of Medicine of the University of California San Diego where he specializes in industrial multi-modality translational and discovery imaging. Previously, Dr. McConville was a Co-Founder and the Chief Scientific Officer at Molecular Imaging Inc., a contract research organization that established the first multi-modality CRO imaging center in Ann Arbor, Michigan.
Dr. McConville received his BSc (Hons) in Physica and Computer Science from the University of New South Wales, Australia, and his PhD in Medical Physics from the Queensland University of Technology, Australia.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. McConville teaches about translational imaging in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 

Daniel Oliver, MBA 

Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a startup out of George Church’s Lab at Harvard Medical School working on reversing aging through the use of novel gene therapies. Prior to Rejuvenate Bio, Mr. Oliver was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Mr. Oliver received his MBA from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Mr. Oliver teaches about cell & gene therapy in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 

David G. Parkes, PhD

Dr. David Parkes has over 25 years of pharmaceutical industry experience in drug discovery and development across multiple therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH), and cardiovascular diseases. He is currently Chief Scientific Officer at Abvance Therapeutics, a pharmaceutical company focused on diabetes, as well as scientific consultant for other pharmaceutical companies, including Astra Zeneca, Gilead, Prosciento, Fractyl, and Prolynx. Earlier, he played pivotal leadership roles at Amylin Pharmaceuticals in the discovery and development of exenatide (BYETTA, BYDUREON), pramlintide (SYMLIN), and metreleptin (MYALEPT), three first-in-class drugs for the treatment of metabolic diseases.
Dr. Parkes received his BSc (Hons) in Pharmacology and his PhD in Pharmacology and Physiology from the University of Melbourne, Australia.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Parkes teaches a drug case study in the Applied Translational Research (CLRE-238) course in the Translational Science Certificate Program.

 

Pierre Rivière, PhD

Dr. Pierre Rivière is a pharmacologist by training with over 25 years of experience in the pharmaceutical industry, primarily in drug discovery and early-stage development of peptide therapeutics. He is the Founder and currently Chief Executive Officer of Peptide Logic, a biopharmaceutical company combining the advantages of synthetic peptides and recombinant antibodies to create innovative semi-synthetic biologics for pain and other pathological conditions in select therapeutic areas. Prior to that, Dr. Rivière  was Chief Scientific Officer of CovX, which was a Pfizer-owned biopharmaceutical company, as well as Senior Vice President of Pfizer Worldwide R&D.
Dr. Riviere received his PhD in Animal Physiology and Biology from the Institut National Polytechnique de Toulouse, France.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Rivière teaches about drug discovery in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 
M. Paz Rodriguez, DDS, MAS

Dr. Paz Rodriguez is a dentist practicing in Santiago, Chile. After completing her Doctorate in Dental Surgery at the Universidad Finis Terrae in Santiago with a Minor in Communications, she obtained a Master of Science in Dental Implant Surgery and Rehabilitation from the Universidad de los Andes in Santiago. More recently, she completed her Master of Advanced Studies in Clinical Research at the University of California, San Diego. At the Altman Clinical and Translational Research Institute of the School of Medicine of the UC San Diego, Dr. Rodriguez is Communication Director of the Translational Science Certificate, leveraging the entrepreneurial and communication expertise that she has developed as a patient-experience-focused independent dentist, and her interest in the transformative potential of translational science in healthcare. She is also Course Co-Director of the Certificate Capstone Project (CLRE-40004) and of the Translational Research Fundamentals (CLRE-236), and Course Manager of Applied Translational Research (CLRE-238) and Applied Translational Research II (CLRE-239). Currently she is living in Santiago, Chile working as a Clinical Process Coordinator for a new Precision Oncology center at the Universidad Mayor’s School of Medicine. The center is one of the first genetics based oncology treatment research centers of the country, and it brings together efforts from academic research, patient oriented clinics, innovative oncology based clinical trials, and genetic testing to create a true translational research center. 

 
Claudio D. Schteingart, PhD

Dr. Claudio Schteingart is currently an independent consultant with over 25 years of experience in the pharmaceutical industry. He retired in 2018 as Vice President, Science & Technology – Research, at Ferring Pharmaceuticals where he was responsible for the evaluation of new technologies for the discovery and development of novel peptide therapeutics, for guiding drug discovery programs, and for supporting drug candidates in development. He contributed to the discovery of the peptidic GnRH antagonist degarelix, launched in 2009 as FIRMAGON, and many other peptidic drug candidates in various stages of clinical development for urology, women’s health, critical care medicine, and gastroenterology.
Dr. Schteingart received a PhD in Chemistry from the University of Buenos Aires, Argentina. After postdoctoral studies in the Department of Chemistry of the University of California, San Diego, he moved to the Department of Medicine where he carried out research in the chemistry, physiology, metabolism, and physicochemical properties of biliary components and lipids.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Schteingart is Course Co-Director of Applied Translational Research (CLRE-238) and Applied Translational Research II (CLRE-239) in the Translational Science Certificate Program.

 
Marina Seme Nelson, PhD 

Dr. Marina Seme Nelson has over 20 years of experience in the pharmaceutical industry and specializes in drug development and nonclinical safety assessment. She is currently Drug Development Leader for Early Phase Development Solutions at the contract research organization LabCorp Drug Development, where she provides scientific and strategic direction to drug development programs and product development. Earlier, Dr. Nelson was Study Director and Drug Safety and Metabolism Representative at the pharmaceutical company Wyeth, where she led multi-disciplinary and global development teams.
Dr. Seme Nelson received her MS in Biotechnology from Northwestern University and her PhD in Pharmacology and Toxicology from the Medical College of Wisconsin.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Seme Nelson teaches about nonclinical development in the Translational Research Fundamentals (CLRE-236) course in the Translational Science Certificate Program.

 
John M. York, PharmD, MBA

Dr. John York is a commercially oriented marketing and medical professional with over 25 years in the pharmaceutical and biotechnology industries across multiples therapeutic areas, including hematology/oncology, ophthalmology, cardiovascular medicine, respiratory medicine, pediatrics, dermatology, and neurology. After assuming various leadership roles at the pharmaceutical companies Bristol-Myers Squibb, Amgen, and Allergan, and at the medical communications and consulting company HDI, he founded the medical communications and consulting company Akita Biomedical where he is currently Chief Executive Officer and Principal. He is also Lecturer and Lead Instructor at the Rady School of Management of the University of California, San Diego.
Dr. York received his PharmD degree from the University of Michigan and completed an Industry Postdoctoral Fellowship jointly offered by Rutgers University, Warner-Lamber, and Parke-Davis. He then obtained an MBA degree from Indiana University, as well as a Life Sciences Business Certificate and a Marketing Certificate from the University of California, Berkeley.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. York is Course Director of the Capstone Project (CLRE-40004) in the Translational Science Certificate Program.

 

Apply Now

What is Translational Science?

Learn more about the Translational Science Certificate!

What is Translational Science?

"The (discipline) turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and populations - from diagnostics and therapeutics, to medical procedures and observational behaviors" - National Center for Advancing Translational Sciences, NIH

Translational-Continuum-updated.png

 

 

Translational science can be divided into four sequential groups of processes:

T1 (Translational to humans): The process of translating scientific observations made in the laboratory, clinic, or community into a proposed biomedical product (anything from a candidate drug or cell & gene therapy to a medical technology--a medical device or a digital health product) demonstrated to work in preclinical models and ready to be tested in humans.

 

T2 (Translation to patients): The process of combining the learnings from Phase 1 clinical trial(s) in human volunteers with the findings from preclinical models to conduct Phase 2 and Phase 3 clinical trials in patients. Phase 2 clinical trials, also known as first-in-patient or clinical proof of concept trials, is where the likelihood of translation failure is the highest (70% failure rate on average).

 

T3 (Translation to practice): The process of taking a biomedical product, now approved by regulatory
authorities (e.g., FDA in the United States) based on preclinical and clinical findings, into clinical practice (i.e., into the "real world").

 

T4 (Translation to community): The process of assessing the impact of a biomedical product used in clinical practice, not only the patients treated with it, but also on its access in the targeted patient populations with all the associated socio-economic implications involving manufacturers, distributors, payers (e.g., insurance companies), and various levels of government--in sum, the public health
impact of the biomedical product.

 

Admission

To apply you need at least one of the following degrees:

  • Academic doctoral degree (e.g., PhD, DPhil, DSc)
  • Professional doctoral degree (e.g., MD, DVM, DMD, DDS, PharmD)

Significant prior exposure to or work experience in medical and/or biomedical science will make the experience more meaningful and fulfilling

Documents that you need to provide with your application:

  • Resume or curriculum vitae (CV)
  • Statement of Purpose

The Certificate Program Admission Committee will judge the applicant competencies on a case-by case basis.

Apply Now

 

Scholarship opportunity

The Certificate Program Admission Committee chooses our recipients carefully. The ideal applicant is either a:

  • Postdoctoral scholar without a fellowship to support course fees.
  • Biomedical industry or healthcare professional from a company that does not offer educational support.

To qualify for financial assistance to offset the cost of the certificate, we require you to have significant prior exposure to or work experience in medical and/or biomedical science. We will offer this scholarship twice a year at the Winter and Summer admission points. Through the scholarship, we cover 80% of the tuition fees per recipient.

 

What we need from you

Your work experience, research experience and overall admission profile can qualify you to receive financial assistance to help offset the cost of your certificate

  • Resume or curriculum vitae (CV)
  • Statement of purpose (read below for more details)
  • Online Zoom Interview
  • Commitment to complete the certificate program within one year

Statement of Purpose 

To apply for the scholarship, please send us a video* describing your career and personal accomplishments, and why you feel you are deserving of such an award from us.
*The video must be in .MP4 format and no longer than 6 minutes.

Include any and all materials that support your case in the email, sent to us together with the video. Be specific and persuasive in your video. We will judge the quality and success of the applicant on a case-by-case basis and will be inclined to give awards to those who best communicate their merits, accomplishments, and future plans.

Key Documents

For any Certificate questions, please contact us directly:
Dr. M. Paz Rodriguez, TSC Communications

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Apply Now